Primary Androgen Deprivation Therapy for Prostate Cancer in Koreans: A Retrospective Multicenter Study.
10.5534/wjmh.2014.32.3.159
- Author:
Won Ik SEO
1
;
Pil Moon KANG
;
Tae Hyo KIM
;
Kyung Hyun MOON
;
Jae Min CHUNG
;
Dong Hyun LEE
;
Isaac Yi KIM
;
Kweonsik MIN
;
Jaeil CHUNG
;
Wansuk KIM
;
Dong Il KANG
Author Information
1. Department of Urology, Inje University College of Medicine, Busan, Korea. urokang@lycos.co.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Androgen antagonists;
Prostate;
Prostate neoplasms
- MeSH:
Androgen Antagonists;
Comorbidity;
Disease-Free Survival;
Humans;
Prostate;
Prostate-Specific Antigen;
Prostatic Neoplasms*;
Retrospective Studies*
- From:The World Journal of Men's Health
2014;32(3):159-166
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate the characteristics of patients who received primary androgen deprivation therapy (PADT) for prostate cancer and the clinical efficacy of this treatment. MATERIALS AND METHODS: Two hundred forty patients treated by PADT were reviewed. These patients could not receive definitive therapy owing to old age, patient need, and medical comorbidity. The patients were divided into three groups according to the extent of prostate cancer: localized, locally advanced, and metastatic. Then, prostate-specific antigen (PSA) progression in these groups was analyzed. RESULTS: The median age of the patients was 73.0 years, and the median pretreatment PSA level was 47.0 ng/mL. Of the patients, 91.7% were treated with combined androgen blockade, and 8.3% were treated with monotherapy. Clinical factors for PSA progression were a PSA nadir and a high clinical stage. Estimated PSA recurrence-free median survival time in each group was 57, 24, and 12 months, respectively. A PSA nadir of >0.2 ng/mL and metastatic stage were independent factors for expecting a poor response to PADT (hazard ratio 4.26, p<0.001; and 2.60, p<0.001). CONCLUSIONS: Patients with localized or locally advanced prostate cancer who did not receive definitive therapy had lower PSA progression rates than those at metastatic stage during PADT. Further, a PSA nadir of < or =0.2 ng/mL showed better progression-free survival. Therefore, PADT can be another therapeutic option in well-selected patients with localized or locally advanced prostate cancer and PSA change should be checked carefully.
